The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis
Latest Information Update: 15 Oct 2015
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Cardiovascular disorders; Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Oct 2015 Results published in the Thrombosis and Haemostasis
- 11 Jun 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
- 23 May 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014; according to ClinicalTrials.gov record.